SCHEMBL956150

SCHEMBL956150

CCC(C(=O)O)c1cccc(OCc2c(C)cccc2C)c1

nearest known ligand 0.50

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 4/20 0.46
AKR1C2 P52895 4/20 0.46
PTGS1 P23219 2/20 0.46
AKR1C1 Q04828 1/20 0.46
SLC22A12 Q96S37 2/20 0.43
KMT2A Q03164 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
FFAR1 O14842 2/20 0.40
ALOX5 P09917 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2745435 1.00 AKR1C3 (0.46) AKR1C3AKR1C2PTGS1AKR1C1SLC22A12
SCHEMBL1008197 0.88 MAPK1 (0.41) SLC22A12KMT2ASMN1; SMN2FFAR1
SCHEMBL1008990 0.85 AKR1C3 (0.50) AKR1C3AKR1C2PTGS1AKR1C1KMT2A
SCHEMBL2745203 0.84 PTGS1 (0.58) AKR1C3AKR1C2PTGS1SLC22A12KMT2A
SCHEMBL2381049 0.84 KMT2A (0.60) KMT2ASMN1; SMN2ALOX5
SCHEMBL954605 0.84 PTGS1 (0.58) AKR1C3AKR1C2PTGS1SLC22A12KMT2A
SCHEMBL1634518 0.83 FFAR1 (0.51) SLC22A12KMT2ASMN1; SMN2FFAR1
SCHEMBL10455351 0.81 KMT2A (0.57) AKR1C3AKR1C2PTGS1AKR1C1KMT2A
SCHEMBL14406985 0.80 SLC22A12 (0.41) PTGS1SLC22A12KMT2ASMN1; SMN2FFAR1
SCHEMBL1135051 0.79 MAPK1 (0.39) SLC22A12KMT2ASMN1; SMN2FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3517109-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID Wellstat Therapeutics Corporation (US) 2019-07-31 EP claimed
US-9115072-B2 Compounds and method for reducing uric acid WELLSTAT THERAPEUTICS CORPORATION (US) 2015-08-25 US claimed
US-20130259850-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2013-10-03 US claimed
US-20110014176-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2011-01-20 US claimed
EP-2268141-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID Wellstat Therapeutics Corporation (US) 2011-01-05 EP claimed
WO-2009151695-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2009-12-17 WO claimed
US-20090203793-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2009-08-13 US claimed
EP-1948152-A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS Wellstat Therapeutics Corporation (US) 2008-07-30 EP claimed
WO-2007056771-A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2007-05-18 WO claimed
EP-3517109-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID Wellstat Therapeutics Corporation (US) 2019-07-31 EP disclosed
EP-3517109-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID Wellstat Therapeutics Corporation (US) 2019-07-31 EP disclosed
EP-2268141-B1 COMPOUND AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORP (US) 2019-05-08 EP disclosed
EP-2268141-B1 COMPOUND AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORP (US) 2019-05-08 EP disclosed
US-9115072-B2 Compounds and method for reducing uric acid WELLSTAT THERAPEUTICS CORPORATION (US) 2015-08-25 US disclosed
US-20090203793-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2009-08-13 US disclosed
US-20090203793-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2009-08-13 US disclosed
US-20090203793-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2009-08-13 US disclosed
EP-1948152-A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS Wellstat Therapeutics Corporation (US) 2008-07-30 EP disclosed
WO-2007056771-A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2007-05-18 WO disclosed
WO-2007056771-A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203793-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS CPT1B, CPT1A, GOT2 AKR1C3 308/4885AKR1C2 222/4885PTGS1 953/4885
US-20130259850-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID RCC2, HAX1, SLC10A6 AKR1C3 1312/4885AKR1C2 1297/4885PTGS1 2742/4885
US-20110014176-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID UGP2, TAS2R46, PYCARD AKR1C3 3316/4885AKR1C2 2679/4885PTGS1 2090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.